+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Longterm effects of hepatic arterial interleukin-2-based immunochemotherapy after potentially curative resection of colorectal liver metastases



Longterm effects of hepatic arterial interleukin-2-based immunochemotherapy after potentially curative resection of colorectal liver metastases



Journal of the American College of Surgeons 187(3): 271-275



Our previous study of hepatic arterial infusion of interleukin-2 (IL-2)-based immunochemotherapy demonstrated a high response rate of patients with unresectable liver metastases. In this study, we applied this therapy to the prevention of liver recurrence in patients who underwent potentially curative resection of liver metastases. A pilot study was conducted of 18 patients with liver metastases from primary colorectal cancer who underwent potentially curative liver resection followed by adjuvant immunochemotherapy. The regimen consisted of a weekly hepatic arterial infusion of IL-2 (1.4-2.1 X 10(6) U) and 5-fluorouracil (250 mg) and a bolus of mitomycin C (2-4 mg) for 6 months. Among 18 patients, 14 are still alive with a median postoperative survival of 52 months (as of April 1998). The 5-year overall survival rate was 75%. Although recurrent cancer developed in 6 of the 18 patients, no patients had recurrence in the residual liver. This complete prevention of liver recurrence is believed to have contributed to the high 5-year survival rate (75%) as compared with the survival rate of patients treated with surgery alone (average, 30%-40%) or with several other forms of adjuvant therapy. Interleukin-2-based immunochemotherapy is useful in combination with liver resection for the prevention of liver recurrence in colorectal cancer patients with liver metastases. A multicenter randomized trial is recommended.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046575072

Download citation: RISBibTeXText

PMID: 9740184

DOI: 10.1016/s1072-7515(98)00157-4


Related references

Hepatic arterial infusions of interleukin-2-based immunochemotherapy in the treatment of unresectable liver metastases from colorectal cancer. Clinical Therapeutics 15(4): 672-683, 1993

Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastases. Journal of the American College of Surgeons 202(1): 100-111, 2006

The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer. Nihon Geka Gakkai Zasshi 101(8): 568-573, 2000

Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases. Hepato-Gastroenterology 43(9): 688-691, 1996

Reasonable approach for prophylactic hepatic arterial infusion chemotherapy after potentially curative surgery for colorectal liver metastases. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(12): 2129-2131, 2002

Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. American Journal of Surgery 166(6): 743, 1993

Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study. European Journal of Surgical Oncology 17(5): 519-525, 1991

Adjuvant hepatic arterial infusion after curative resection of colorectal liver metastases using removable intra-arterial catheters with shape-memory alloy. Journal of Surgical Oncology 88(4): 248-255, 2004

Complete Remission of Liver Metastases from Colorectal Cancer by Treatment with a Hepatic Artery Infusion (HAI) of Interleukin-2-Based Immunochemotherapy: Reports of Three Cases. Surgery Today 24(1): 80-84, 1994

Management of hepatic arterial infusion port following prophylactic regional chemotherapy in patients who have undergone curative resection of colorectal liver metastases. Surgery Today 33(9): 679-683, 2003

Systemic or hepatic arterial chemotherapy after curative resection of liver metastases from colorectal cancer. A meta-analysis of randomized controlled trials. Journal of Clinical Oncology 26(15_Suppl): 4077-4077, 2016

Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study. Cancer 88(7): 1549-1556, 2000

Interleukin-2 as a modulator of 5-fluorouracil in hepatic arterial immunochemotherapy for liver metastases. Hepato-Gastroenterology 47(32): 487-491, 2000

Intermittent hepatic arterial infusion of high-dose fluorouracil on a weekly schedule as adjuvant chemotherapy following curative resection of colorectal liver metastases: a randomized study. Journal of Clinical Oncology 23(16_Suppl): 3727-3727, 2016

Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection. Hepato-Gastroenterology 59(116): 1087-1090, 2012